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Purpose. To determine the importance of PEPT2 in the uptake of
glycylsarcosine (GlySar) and 5-aminolevulinic acid (5-ALA) in
mouse choroid plexus whole tissue.
Methods. Uptake studies were performed in bicarbonate artificial
cerebrospinal fluid buffer using choroid plexuses isolated from
PEPT2+/+ and PEPT2−/− mice. [14C]GlySar and [14C]5-ALA were
studied as a function of temperature, concentration, potential inhibi-
tors, and low sodium conditions.
Results. PEPT2−/− mice exhibited a 90% reduction in GlySar uptake
(p < 0.001) and a 92% reduction in 5-ALA uptake (p < 0.001) as
compared to wild type animals. At 4°C (vs. 37°C), GlySar uptake was
reduced by 95% in PEPT2+/+ mice; no difference was observed in null
animals. Unlabeled GlySar inhibited the uptake of [14C]GlySar in
PEPT2+/+ mice (p < 0.01); self-inhibition did not occur in PEPT2−/−
mice. GlySar demonstrated saturable uptake in PEPT2+/+ mice (Vmax
 16.4 pmol mg−1 min−1, Km  70 M, Kd  0.014 l mg
−1 min−1),
however, uptake was linear in PEPT2−/− mice (Kd  0.023 l mg
−1
min−1). Low sodium buffer (1 mM) resulted in 75% and 59% reduc-
tions, respectively, in GlySar (p < 0.001) and 5-ALA (p < 0.01) uptake
in PEPT2+/+ mice; no differences were observed in PEPT2−/− mice.
Overall, about 90–95% of the choroid plexus uptake of GlySar and
5-ALA was mediated by PEPT2, with about 5–10% of the residual
uptake occurring by nonspecific mechanisms.
Conclusions. The results demonstrate that PEPT2 is the only trans-
porter responsible for the choroid plexus uptake of GlySar and
5-ALA. They also suggest a role for PEPT2 in the clearance of di-
peptides and endogenous peptidomimetics from cerebrospinal fluid.
KEY WORDS: 5-ALA; choroid plexus; GlySar; knockout mouse;
PEPT2.
INTRODUCTION
The choroid plexus is a highly vascularized single layer of
cuboidal epithelium that lines the ventricles of the brain and
produces 65–75% of cerebrospinal fluid (CSF) in humans (1).
In addition, the choroid plexus functions as an important
physiologic and pharmacologic barrier, commonly referred to
as blood-CSF-barrier (BCSFB) (2). The BCSFB is created
through the formation of tight junctions between the choroi-
dal epithelial cells and by detoxification systems, which may
include membrane-bound efflux transporters. These trans-
porters not only serve a critical role in protecting the brain
from potentially toxic endo- and xenobiotics, but are also
important in selectively regulating the distribution of many
physiologically and pharmacologically important compounds
between the blood and CSF.
PEPT2, one of four current members of the mammalian
proton-coupled oligopeptide transporter family (i.e., PEPT1,
PEPT2, PHT1, PHT2) (3), is an electrogenic, sodium-
independent transporter that translocates small peptides
(i.e., sequence independent di-and tripeptides) along with
protons across biologic membranes via an inwardly directed
electrochemical gradient of protons. It was initially cloned
from a human kidney cDNA library (4) and is characterized
as a high affinity (i.e., M Km values), low capacity trans-
porter (5). PEPT2 mRNA transcripts (6,7), protein (8,9) and
functional activity (10–14), along with PHT1 mRNA tran-
scripts (15) have been described in the choroid plexus.
Functional and immunocytochemical data in primary cultures
of rat choroid plexus epithelial cells have demonstrated
that PEPT2 is expressed on the apical plasma membrane
(i.e., CSF-facing) and functions to clear di- and tripeptides
from CSF (9). The functional role of PHT1 still remains un-
certain.
The recent generation of PEPT2 knockout mice by this
laboratory (13) and by Rubio-Aliaga and coworkers (16) has
provided a powerful tool to directly examine the physiologic
and pharmacologic significance of PEPT2 in the transport of
small peptides and peptidomimetics in multiple organ sys-
tems. Recent results have provided strong evidence that
PEPT2 is the primary transporter for uptake of carnosine
(-alanyl-L-histidine) and cefadroxil (aminocephalosporin) at
the BCSFB (12,14). However, in the cefadroxil study (12),
there was a secondary component mediated by an organic
anion transporter, the relative importance of which varied
with concentration. The possibility that multiple transporters
may be involved in the transport of peptides and peptidomi-
metics emphasizes the importance of expanding our knowl-
edge of the relative role PEPT2 in transport at the choroid
plexus. Although there is evidence for the PEPT2-mediated
uptake of glycylsarcosine (GlySar) and 5-aminolevulinic acid
(5-ALA) into choroid plexus, sodium removal significantly
reduces transport (8,10). Considering that PEPT2 is a sodium-
independent transporter, this suggests the possibility of an
unidentified second transporter for such compounds (8,10).
GlySar is a synthetic, hydrolysis- and peptidase-resistant di-
peptide commonly used for peptide transport studies. 5-ALA
is an endogenous peptidomimetic substrate for PEPT2
(8,17,18). It is a precursor of porphyrins and heme, and has
been used as a photosensitizer in photodynamic therapy for
various tumors.
With this in mind, the objective of this study was to de-
termine the importance of PEPT2 in the uptake of GlySar
and 5-ALA by the choroid plexus. Studies were performed
using whole-tissue choroid plexus preparations isolated from
wild-type and PEPT2 null mice. Our findings conclusively
demonstrate that PEPT2 has a critical role in the trafficking
of small peptides and endogenous peptidomimetic com-
pounds at the BCSFB.
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MATERIALS AND METHODS
All studies were carried out in accordance with the
Guide for the Care and Use of Laboratory Animals as
adopted and promulgated by the U.S. National Institutes of
Health (NIH publication No. 85-23, revised in 1985).
Materials
[14C]GlySar (106 mCi/mmol) was supplied by Amersham
Biosciences (Chicago, IL), [14C]5-ALA (51.5 mCi/mmol) by
New England Nuclear Life Science Products (Boston, MA),
and [3H]mannitol (17 Ci/mmol) by Perkin Elmer Life Sci-
ences Inc. (Boston, MA). Nylon net filters (100 m) were
obtained from Millipore Co. (Billerica, MA). Dimethylamilo-
ride (DMA) and unlabeled GlySar were obtained from Sigma
(St. Louis, MO), and hyamine hydroxide from ICN (Irvine,
CA). All other chemicals were obtained from standard
sources. PEPT2-transgenic mice were generated on a
C57BL/6 mouse background and genotyped by RT-PCR, as
described previously by Shen et al. (13).
Transport Buffers
Uptake experiments were performed in bicarbonate ar-
tificial CSF (aCSF) buffer (pH 7.4). aCSF buffer was continu-
ously bubbled with 5% CO2, 95% O2 and contained 127 mM
NaCl, 20 mM NaHCO3, 2.4 mM KCl, 0.5 mM KH2PO4, 1.1
mM CaCl2, 0.85 mM MgCl2, 0.5 mM Na2SO4, and 5.0 mM
glucose (pH 7.4). Low sodium (1 mM) aCSF buffer was pre-
pared by substituting choline chloride for NaCl and choline
bicarbonate for NaHCO3.
GlySar and 5-ALA Uptake
All uptake experiments were performed in parallel for
PEPT2+/+ and PEPT2−/− littermates (6-8 weeks old). Detailed
methods for the surgical isolation of the choroid plexus are
described in Keep and Xiang (19) for glutamine uptake.
Briefly, the lateral and fourth ventricle choroid plexuses were
isolated from anesthetized (pentobarbital; 65 mg/kg i.p.)
mice, weighed and transferred to bicarbonate aCSF buffer at
37°C. Each sample consisted of six pooled plexuses from two
animals. A 5-min recovery period was allowed before the
beginning of each experiment. After the recovery period, the
plexuses were transferred to 0.95 ml of transport buffer, with
or without a potential inhibitor, for 0.5 min. Uptake was ini-
tiated by addition of 0.05 ml of buffer with approximately 0.2
Ci of [14C]GlySar (1.9 M) or [14C]5-ALA (5.0 M) and 0.4
Ci of [3H]mannitol (an extracellular marker). Unless other-
wise stated, the uptake was terminated after 3 min for GlySar
or 2 min for 5-ALA by transferring the plexuses to ice-cold
buffer and filtering under reduced pressure. The uptake time
for each compound was based on previous time course data
obtained in rat choroid plexus whole tissue (8,10). The filters
(100-m) were washed three times with cold transport buffer.
The filters and choroid plexuses were then soaked in 0.33 ml
of 1 M hyamine hydroxide (a tissue solubilizer) for 30 min
before the addition of Ecolite (+) scintillation cocktail (ICN;
Irvine, CA) and counting with a dual-channel liquid scintilla-
tion counter (Beckman LS 3801; Fullerton, CA).
The uptake of radiolabeled substrate into choroid plexus,
in microliters per milligram of wet tissue weight, was calcu-
lated as (19):
Substrate Uptake =
(St − Sf) − (Mt − Mf)  ratio
Smedia
(1)
where St is the total substrate concentration in the plexus
plus filter, Sf is the filter binding of substrate, and Smedia is
the substrate concentration in the external media. The (Mt −
Mf) · ratio term is a correction for extracellular space, where
Mt is the total mannitol concentration in the plexus plus filter
and Mf is the filter binding of mannitol. Multiplying this dif-
ference by the ratio of [14C] to [3H] in the external medium
provides an estimate of the extracellular content of each sub-
strate. The unidirectional influx rate (V) can then be calcu-
lated by multiplying substrate uptake by Smedia and dividing
by the duration of the experiment.
Data Analysis
For kinetic studies, the concentration-dependent uptake





+ Kd  C (2)
where Vmax is the maximal rate of saturable uptake, Km is the
Michaelis constant, Kd is the rate constant for nonsaturable
processes, and C is the substrate concentration.
To evaluate if more than one class of transporters was
operational for GlySar uptake, a Woolf-Augustinsson-
Hofstee transformation was performed on the saturable com-
ponent of Eq. 2 (v  V – Kd C) such that:
v = Vmax − Km (vC) (3)
All data are reported as mean ± SE. Statistical comparisons
were performed with ANOVA (GraphPad Prism, v3.0;
GraphPad Software, Inc., San Diego, CA) and post hoc pair-
wise comparisons made with Dunnett’s test. A probability of
p  0.05 was considered statistically significant. Linear and
nonlinear regression analyses were performed with SigmaPlot
8.0 (SPSS Inc., Chicago, IL) and a weighting factor of unity.
The quality of fit was determined by evaluating the coefficient
of determination (r2), the coefficient of variation (CV%) of
parameter estimates, and by visual inspection of the residuals.
RESULTS
GlySar Uptake
PEPT2−/− mice exhibited a significantly reduced uptake
rate of 1.9 M GlySar (i.e., 90.1%) under physiologic condi-
tions (pH 7.4, 37°C), as compared to PEPT2+/+ mice (p <
0.001; Fig. 1). Temperature had a dramatic effect on GlySar in
which uptake was reduced by 96% at 4°C (vs. 37°C) in
PEPT2+/+ mice. In contrast, no significant reduction was ob-
served in PEPT2 null animals at the lower temperature. The
uptake rate of 1.9 M [14C]GlySar (pH 7.4, 37°C) was sub-
sequently examined in the presence of saturating concentra-
tions of unlabeled substrate (5 mM). It was found that in
PEPT2+/+ mice, excess GlySar reduced the uptake of radio-
labeled GlySar to values observed at 4°C for both genotypes,
and to uptake rates observed at 37°C in PEPT2−/− mice in the
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absence of inhibitors. Self-inhibition of radiolabeled GlySar,
on the other hand, was conspicuously absent in PEPT2−/−
mice.
The concentration-dependent uptake of GlySar (1–1000
M) was investigated in both genotypes under physiologic
conditions (Fig. 2A). PEPT2+/+ mice demonstrated saturable
transport with a maximum velocity (Vmax) of 16.4 ± 0.9 pmol
mg−1 min−1, a Michaelis constant (Km) of 70 ± 9 M, and a
nonsaturable rate constant (Kd) of 0.014 ± 0.001 l mg
−1
min−1. A Woolf-Augustinsson-Hofstee transformation of the
saturable uptake component (v) in PEPT2+/+ mice demon-
strates strong linear behavior (Fig. 2B; r2  0.984), indicating
the presence of one class of transporters. Under linear con-
ditions, the carrier-mediated component accounted for 95%
of transport, while the nonspecific uptake component com-
prised only 5% of the total uptake in PEPT2+/+ mice. In con-
trast, PEPT2−/− mice exhibited a much less efficient transport
(Kd only of 0.023 ± 0.001 l mg
−1 min−1). These results sug-
gested the lack of additional carriers for GlySar and further
strengthened the argument that PEPT2 was the only trans-
porter involved in GlySar uptake at the mouse choroid
plexus. Based on the calculated Kd in PEPT2
+/+ mice, the
nonsaturable uptake rate at 1.9 M was estimated to be 0.028
pmol mg−1 min−1, a value that compares very well to the
uptake rate of 1.9 M GlySar in PEPT2+/+ mice observed at
4°C (i.e., 0.033 pmol mg−1 min−1; Fig. 1). A complete sum-
mary of the kinetic data is provided in Table I.
Dimethylamiloride (DMA; 100 M), an inhibitor of the
Na+/H+ exchanger (20,21), significantly reduced the uptake
rate of GlySar in PEPT2+/+ mice (i.e., 60.3% reduction; p <
0.01), suggesting that a Na+/H+ exchange-generated pH gra-
dient is important for uptake (Fig. 1). In contrast, DMA had
no effect on the uptake rate of GlySar in PEPT2−/− mice. Low
sodium aCSF buffer (1 mM) resulted in a 75% reduction in
the uptake of 1.9 M GlySar in PEPT2+/+ mice (p < 0.001; Fig.
3), however, it did not alter the uptake rate of GlySar in
PEPT2−/− mice. Since a Na-dependent uptake was found only
in the presence of PEPT2, the reduced uptake of GlySar
Table I. GlySar Uptake Kinetics in Wild-Type and PEPT2 Null Animals
Parameter* PEPT2+/+ PEPT2−/−
Vmax (pmol mg
−1 min−1) 16.4 (0.9) —
Km (M) 70 (9) —
Kd (l mg
−1 min−1) 0.014 (0.001) 0.023 (0.001)
Vmax/Km (l mg
−1 min−1) 0.23 —
r2 0.999 0.993
* Parameter estimates (± SE) were derived by nonlinear (or linear)
regression models. r2 is the coefficient of determination.
Fig. 1. Uptake rate of [14C]GlySar (1.9 M GlySar in external media)
in PEPT2+/+ and PEPT2−/− mice as a function of temperature and
potential inhibitors. Studies were performed in bicarbonate aCSF
buffer (pH 7.4; 37°C), unless otherwise noted. Data are expressed as
mean ± SE (n  4 to 6). Dimethylamiloride (DMA) was present at
100 M and unlabeled GlySar was present at 5 mM. *p < 0.01 as
compared to control values for each genotype.
Fig. 2. (A) Concentration-dependent uptake rate of [14C]GlySar (1–
1000 M total GlySar in external media) in PEPT2+/+ () and
PEPT2−/− mice (). Predicted curves were generated using Vmax, Km,
and Kd values reported in the text and Table I. Studies were per-
formed in bicarbonate aCSF buffer (pH 7.4; 37°C). Data are ex-
pressed as the mean of two preparations, where each preparation
consists of six pooled plexuses from two mice. (B) Woolf-
Augustinsson-Hofstee transformation of the saturable uptake com-
ponent (v) in PEPT2+/+ mice (r2  0.984).
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probably reflects an indirect effect via inhibition of Na+/H+
exchange.
5-ALA Uptake
Under physiologic conditions (i.e., normal sodium-
containing aCSF buffer, 37°C), the influx rate of 5.0 M
5-ALA was reduced by 92.3% in PEPT2 null mice, as com-
pared to wild-type controls (Fig. 4; p < 0.001). Low sodium
aCSF buffer (1 mM) resulted in a 59% reduction in the up-
take of 5-ALA in PEPT2+/+ mice (p < 0.01; Fig. 3) but, as
observed with GlySar, it did not significantly alter the uptake
rate of 5-ALA in PEPT2−/− mice.
DISCUSSION
Gene knockout is an elegant approach for obtaining new
insights into the physiologic and pharmacologic significance
of transport proteins that belong to multiple gene families.
Results from this approach are just beginning to emerge for
the PEPT2-mediated transport of peptides/mimetics at the
choroid plexus (12–14). This paper extends these findings and
indicates that PEPT2 is the sole carrier for GlySar and 5-ALA
transport in isolated choroid plexus.
PEPT2 transports a wide range of di- and tripeptides in
the kidney and brain (3,5,9–11,14,22). GlySar has often been
used as a model substrate for peptide transport studies be-
cause it is hydrolysis and peptidase resistant. In our initial
study describing the development of transgenic mice (13), a
marked reduction in the choroid plexus uptake of GlySar was
noted in the PEPT2 null animals. However, these experi-
ments were limited by the use of nonphysiologic Tris-Mes
buffer and conditions that were optimized for PEPT2 trans-
port (i.e., at pH 6.5). Moreover, inhibition experiments as well
as concentration- and temperature-dependent studies were
not performed and, as a result, the authors could not exclude
the possibility that other transporters were involved in GlySar
uptake. The present study was performed using physiologic
conditions (i.e., aCSF buffer, at pH 7.4), and demonstrated
that the choroid plexus uptake rate for GlySar was substan-
tially reduced (∼90%) in PEPT2 null mice.
Analyses of the transport kinetics of GlySar in choroid
plexus indicate that (under linear conditions) the active up-
take mechanism accounts for 95% of total uptake in wild-type
controls. The kinetic analyses also show that only one class of
transporters mediate GlySar uptake in PEPT2+/+ mice, a find-
ing that is consistent with the lack of saturability observed in
PEPT2−/− mice. The estimated transport parameters for
PEPT2 in wild-type mice are also similar to findings in other
experimental systems. The Michaelis constant for GlySar up-
take in our system (Km  70 M) is comparable to values
reported for the PEPT2-mediated uptake of GlySar in cho-
roid plexus whole tissue from rat (Km  129 M) (10) and in
neonatal rat choroid plexus cells in primary culture (Km  60
M) (9). Teuscher et al. (14) also found that PEPT2 is re-
sponsible for approximately 95% of the choroid plexus up-
take of the neuropeptide, carnosine (-alanyl-L-histidine). In
combination with the current results for GlySar, PEPT2 ap-
pears to be the primary, if not sole, transporter responsible
for dipeptide clearance from CSF at the choroid plexus.
In addition to small peptides, PEPT2 transports peptido-
mimetics. In particular, PEPT2 has been shown to transport a
number of pharmacologically active agents including -lac-
tam antibiotics (e.g., -amino containing penicillins and
cephalosporins), angiotensin converting enzyme inhibitors
and nucleoside analog prodrugs (23), as well as 5-ALA
(8,17,18). Experiments on whole-tissue choroid plexus prepa-
rations isolated from wild-type and PEPT2 null mice demon-
strated that (under linear conditions) the uptake of cefadroxil
is primarily mediated by PEPT2 (80–85%), and to a minor
extent by an organic anion transporter(s) (10–15%) and non-
specific, temperature-independent mechanisms (5%) (12).
The current study examined the endogenous peptidomimetic
5-ALA. The choroid plexus uptake rate of 5-ALA was sub-
stantially reduced (∼92%) in PEPT2 null mice under physi-
ologic conditions. Previous kinetic data in rat choroid plexus
whole tissue estimated a Km for 5-ALA of 260 M (8). Thus,
the 5-ALA concentration used in these studies (i.e., 5 M)
was well below the level at which saturation might occur.
Given that physiologic concentrations of 5-ALA in humans
are ∼92 nM in plasma and 19 nM in CSF (24), the high-affinity
Fig. 3. Uptake rate of [14C]GlySar (1.9 M GlySar in external media)
in PEPT2+/+ and PEPT2−/− mice as a function of sodium. Studies were
performed in bicarbonate aCSF buffer (pH 7.4; 37°C) under normal
sodium (+Na) and low sodium (−Na) conditions. Data are expressed
as mean ± SE (n  3). **p < 0.001 as compared to normal sodium
buffer for each genotype.
Fig. 4. Uptake rate of [14C]5-ALA (5.0 M 5-ALA in external me-
dia) in PEPT2+/+ and PEPT2−/− mice as a function of sodium. Studies
were performed in bicarbonate aCSF buffer (pH 7.4; 37°C) under
normal sodium (+Na) and low sodium (-Na) conditions. Data are
expressed as mean ± SE (n  4). *p < 0.01 as compared to normal
sodium buffer for each genotype.
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transport kinetics of PEPT2 appears to be well suited for the
efficient removal of 5-ALA (as well as small peptides) from
the CSF. In combination with the findings of Ocheltree et al.
(12), these results suggest that PEPT2 plays an important role
in the trafficking of endogenous and exogenous peptidomi-
metics between CSF and blood.
Previous studies in rat choroid plexus whole tissue (8,10)
have suggested the presence of both sodium-dependent and
sodium-independent uptake mechanisms for GlySar and
5-ALA. However, in these studies it was difficult to ascertain
whether or not sodium removal reduced PEPT2 transport
activity via an indirect effect on Na+/H+ exchange. In the
current study, sodium removal and inhibition of the Na+/H+
exchanger (via DMA) had profound effects on peptide/
mimetic uptake. For example, the choroid plexus uptake of
GlySar and 5-ALA was reduced by 75% and 59%, respec-
tively, in PEPT2+/+ mice, but was unaffected in PEPT2−/−
mice upon removal of sodium from aCSF buffer. Moreover,
uptake was almost completely abolished in the null animals,
as compared to wild type controls. Likewise, inhibition stud-
ies with DMA showed a 60% reduction in the choroid plexus
uptake of GlySar in PEPT2+/+ mice, with no effect in null
animals. These results suggest that the driving force for pep-
tide/mimetic uptake in choroid plexus occurs via an extracel-
lular to intracellular electrochemical proton gradient gener-
ated by a Na+/H+ exchange mechanism. Further, the proton-
motive force is needed for maximal PEPT2-mediated
transport. Finally, it should be appreciated that GlySar and
5-ALA demonstrated a very similar pattern of choroid plexus
uptake, under low sodium conditions, as previously reported
for carnosine (14). These studies with GlySar, 5-ALA and
carnosine are reinforcing and argue against residual sodium-
dependent mechanisms being present for their uptake in cho-
roid plexus.
Although the peptide/histidine transporters PHT1 (15)
and PHT2 (25) have been cloned from brain, and PHT1 tran-
scripts have been found in choroid plexus, several factors
argue against these transporters being involved in GlySar or
5-ALA uptake. In our studies with PEPT2 null mice, there
was no difference in radiolabeled GlySar uptake when pre-
sented with DMA, excess unlabeled dipeptide, low sodium
buffer or reduced temperature (4°C). These findings lend fur-
ther support to previous observations in which saturating con-
centrations of L-histidine could not inhibit the uptake of
[14C]GlySar in rat choroid plexus epithelial cells in primary
culture (9) or in rat choroid plexus whole tissue (10). Despite
the uncertain function of PHT1 and PHT2 in the body, recent
data have suggested an intracellular localization (25,26), po-
tentially serving a role in the intracellular trafficking of small
peptides. Preliminary studies using semi-quantitative PCR
(i.e., PHT1/GAPDH) also suggested that PHT1 levels were
not different in the choroid plexuses of wild type versus null
animals (unpublished observation).
In conclusion, our studies have characterized the func-
tional significance of PEPT2 in the transport of GlySar and
5-ALA at the BCSFB. These findings conclusively demon-
strate that PEPT2 is the sole carrier for GlySar and 5-ALA
transport in the choroid plexus. Only a small percentage (i.e.,
5–10%) of the total uptake was governed by nonspecific, tem-
perature-independent processes. Moreover, the data suggest
a role for PEPT2 in the clearance of small peptides and en-
dogenous peptidomimetic substrates from CSF. Future stud-
ies will be directed at the in vivo pharmacokinetics and tissue
distribution of peptides/mimetics in wild type and PEPT2
knockout mice, in an attempt to determine the role and im-
portance of PEPT2 on a multi-organ level.
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